Quantbot Technologies LP Lowers Stock Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Quantbot Technologies LP lessened its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 60.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,650 shares of the medical instruments supplier's stock after selling 5,550 shares during the quarter. Quantbot Technologies LP's holdings in LeMaitre Vascular were worth $336,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of LMAT. Allspring Global Investments Holdings LLC lifted its stake in LeMaitre Vascular by 48.2% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 13,321 shares of the medical instruments supplier's stock worth $1,227,000 after purchasing an additional 4,330 shares in the last quarter. Townsquare Capital LLC boosted its position in shares of LeMaitre Vascular by 38.0% during the 3rd quarter. Townsquare Capital LLC now owns 47,953 shares of the medical instruments supplier's stock valued at $4,454,000 after acquiring an additional 13,210 shares during the last quarter. Barclays PLC grew its holdings in shares of LeMaitre Vascular by 394.5% in the third quarter. Barclays PLC now owns 36,577 shares of the medical instruments supplier's stock valued at $3,396,000 after purchasing an additional 29,180 shares during the period. Compass Planning Associates Inc acquired a new stake in LeMaitre Vascular during the fourth quarter worth about $567,000. Finally, Charles Schwab Investment Management Inc. raised its stake in LeMaitre Vascular by 6.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 191,511 shares of the medical instruments supplier's stock worth $17,789,000 after purchasing an additional 11,395 shares during the period. 84.64% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Insider Transactions at LeMaitre Vascular

In related news, insider Trent G. Kamke sold 2,009 shares of the firm's stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $82.12, for a total transaction of $164,979.08. Following the transaction, the insider now owns 5,564 shares in the company, valued at $456,915.68. This trade represents a 26.53 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 10.79% of the company's stock.

Analysts Set New Price Targets

LMAT has been the subject of a number of recent analyst reports. Oppenheimer downgraded shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Friday, February 28th. StockNews.com lowered shares of LeMaitre Vascular from a "buy" rating to a "hold" rating in a report on Friday, December 13th. Barrington Research cut shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Lake Street Capital lifted their price target on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the company a "buy" rating in a research report on Friday, February 28th. Finally, Wells Fargo & Company initiated coverage on shares of LeMaitre Vascular in a report on Thursday, February 13th. They issued an "equal weight" rating and a $95.00 price objective on the stock. Five equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, LeMaitre Vascular has an average rating of "Moderate Buy" and a consensus price target of $95.25.

LeMaitre Vascular Stock Performance

Shares of NASDAQ:LMAT traded up $1.46 during trading on Wednesday, hitting $86.62. The company's stock had a trading volume of 198,464 shares, compared to its average volume of 154,759. The company has a market capitalization of $1.95 billion, a PE ratio of 47.33, a P/E/G ratio of 2.22 and a beta of 0.89. The business has a 50 day moving average price of $92.25 and a two-hundred day moving average price of $94.31. LeMaitre Vascular, Inc. has a fifty-two week low of $62.39 and a fifty-two week high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.49. The business had revenue of $55.81 million during the quarter, compared to analysts' expectations of $55.99 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. As a group, equities analysts expect that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 27th. Shareholders of record on Thursday, March 13th were paid a $0.20 dividend. The ex-dividend date of this dividend was Thursday, March 13th. This is a boost from LeMaitre Vascular's previous quarterly dividend of $0.16. This represents a $0.80 dividend on an annualized basis and a yield of 0.92%. LeMaitre Vascular's dividend payout ratio (DPR) is currently 41.24%.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.